Clinical trial
Interleukin-4 (IL-4) as a Marker of Atherosclerosis
NCT00256035 · Melbourne Health, Other · Withdrawn
Key facts
| NCT number | NCT00256035 |
|---|---|
| Title | Interleukin-4 (IL-4) as a Marker of Atherosclerosis |
| Official title | IL-4 as a Marker of Atherosclerosis |
| Lead sponsor | Melbourne Health, Other |
| Collaborators | The Intensive Care Unit Departmental Funding |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Atherosclerosis, Ischemic Heart Disease |
| Intervention type | Procedure |
| Interventions | Measuring IL-4 levels |
| Enrollment | 0 |
| First posted | Nov 21, 2005 |
| Last update posted | Apr 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: